Head-to-head for women
Henry Meds vs Zealthy
Henry Meds and Zealthy both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Metabolic-Fit Score — our women's-health rubric.
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Prices and terms come from the company's own published pages. This is background reading, not medical advice.
Henry Meds
Higher scoreMetabolic-Fit 81/100 · Grade B−
Metabolic-Fit / 100
Best for: Someone comfortable with the stated plan commitment who confirms the full prescribed treatment cost before paying.
Visit Henry MedsZealthy
Metabolic-Fit 33/100 · Grade C
Metabolic-Fit / 100
Best for: Nothing, while the federal case is open. It stays on the board for transparency, not as a suggestion.
Visit ZealthyThe verdict for women
Henry Meds edges out Zealthy on the Metabolic-Fit Score, 81 to 33 (B− vs C). Someone comfortable with the stated plan commitment who confirms the full prescribed treatment cost before paying.
Zealthy is still a genuine option — fDA warning letter #716501 (Sept. 2025), which names Zealthy's website, and in April 2026 the FTC and DOJ moved to seize the company and freeze its assets. Read both before anything else here. Semaglutide: Medication from $151/mo; total program cost requires confirmation; tirzepatide: Current public tirzepatide cash total not itemized. The medication sticker does not establish total program cost, and no current tirzepatide cash total is itemized publicly. Weigh the six women's-health factors below against your own priorities.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
Price highlights compare average monthly budgets, using 52 weeks ÷ 12 months for weekly cycles. Quoted charges retain their billing units; unknown periods and fee-only or prepaid quotes do not compete.
| Detail | Henry Meds | Zealthy |
|---|---|---|
| Metabolic-Fit Score | 81/100 · B− | 33/100 · C |
| Overall rank | #7 | #309 |
| Semaglutide | $297/mo | Total price unconfirmed; medication advertised from $151/mo |
| Tirzepatide | Oral: $891 prepaid for a listed 3-month supply; injection price unconfirmed | Current public tirzepatide cash total not itemized |
| Coverage | Multi-state | Most states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
The decision beyond the score
An incomplete low price cannot settle this comparison
Henry Meds publishes compounded semaglutide injections at $297 monthly. Zealthy's public medication starting figure is $151, but the current public offer does not fully itemize required program charges or working-dose conditions. The apparent difference cannot be described as a verified saving on complete care. An insured brand copay offer is also conditional on eligibility and coverage; it is not the cash cost of a compounded program. Ask Zealthy for a written total covering medication, recurring service charges and the amount due at the next refill before placing it beside Henry's program price.
The tirzepatide side is less comparable still. Zealthy's current public cash total is not itemized. Henry's established public offer is oral tirzepatide at $891 paid in full for a listed three-month supply, with conflicting duration wording in the same program section. That is not evidence of a current Henry injectable price. Someone comparing injections should obtain two injection quotes with matching supply periods and prescribed doses. Someone considering an oral preparation should discuss that formulation directly with the prescriber rather than treating its monthly equivalent as the cost of an injectable alternative.
The enforcement history is a material decision factor
In April 2026, the FTC and DOJ sought receivership and an asset freeze concerning Zealthy, alleging problems with disclosures, cancellation, reviews and use of clinicians' identifiers. Those allegations are not findings of liability, and the existence of the action does not establish the present procedural status of the case. It does give a prospective customer a concrete reason to check the contracting entity, billing authorization and route for ending charges. A modest-looking medication amount does not answer the questions raised by that history.
Separately, the FDA issued FitRX, LLC dba Zealthy warning letter #716501 on September 9, 2025, naming getzealthy.com. Other FDA letters name the same operator under different trading names; those should not be misrepresented as additional letters naming this storefront. Henry's practical comparison is a more fully priced compounded menu, including prepaid semaglutide options, rather than a guarantee of satisfactory care. Before choosing either, confirm the prescriber relationship, dispensing details and cancellation terms for the precise plan. The unresolved Zealthy total and documented enforcement concerns deserve resolution before any claimed cost advantage carries weight.
Based on the public terms documented in the Henry Meds review and Zealthy review. Each review details the prices and terms. Confirm current terms before paying.
Metabolic-Fit / 100
Henry Meds
Metabolic-Fit 81/100 · Grade B−
What we like
- An established operator with a long, visible track record
- Some states allow an independent provider review without a scheduled video call
- Semaglutide: $297/mo; tirzepatide: Oral: $891 prepaid for a listed 3-month supply; injection price unconfirmed.
The caveats
- Compounded only, and no pregnancy or postpartum framing
- The oral tirzepatide section lists a three-month supply at $891 paid in full, but its delivery text conflicts on duration; injectable tirzepatide pricing needs confirmation.
Metabolic-Fit / 100
Zealthy
Metabolic-Fit 33/100 · Grade C
What we like
- Semaglutide: Medication from $151/mo; total program cost requires confirmation; tirzepatide: Current public tirzepatide cash total not itemized.
The caveats
- No dedicated postpartum, breastfeeding, or PCOS framing
- April 2026: the FTC and DOJ asked a federal court to place Zealthy in receivership and freeze its assets, alleging deceptive disclosures, obstructive cancellation and review manipulation
- The same complaint alleges misuse of clinicians' NPI numbers to issue prescriptions without their knowledge or consent — the government's words are that Zealthy is "actively deceiving telehealth patients, endangering their safety, and raiding their bank accounts". These are allegations, not findings; the case is ongoing
Some outbound links earn MomMetabolic a referral fee at no added cost to you, walled off from the Metabolic-Fit Score. Pricing, states and verification reflect each provider's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Comparisons close to Henry Meds vs Zealthy.
- Henry Meds vs Ro
- Henry Meds vs Hers
- CoreAge Rx vs Henry Meds
- CoreAge Rx vs Enhance MD
- CoreAge Rx vs Embody
- Hers vs Zealthy
Or browse the full comparison hub.